CNV1014802 is primarily investigated for its potential therapeutic applications in the treatment of neurological disorders. It has shown promise in preclinical studies as a selective sodium channel blocker, which may help in managing conditions like epilepsy and neuropathic pain. The compound’s ability to modulate neuronal excitability makes it a candidate for reducing seizure activity and alleviating chronic pain symptoms. Additionally, researchers are exploring its efficacy in addressing bipolar disorder and other mood-related conditions due to its impact on neural pathways. Its development is focused on creating a safer and more effective alternative to existing treatments with fewer side effects. Ongoing clinical trials aim to further validate its therapeutic potential and optimize its use in medical practice.